Health Care

Ardelyx’s latest earnings reveal a biotech firm focused on GI‑centric metabolic drugs, trading at $5.73 with a $1.41B market cap and high investor confidence.

Discover Zentek Ltd.’s latest market update: volatile share prices, negative earnings yet promising nano‑material growth, and future‑focused investment insights.

Arvinas Inc. gears up for a Q4 2025 earnings report, engaging investors via conferences and positioning itself in the $4.53 bn targeted protein degradation market poised for 32% CAGR growth to 2033.

Axogen Inc.

Harmony Biosciences wins FDA approval for WAKIX in pediatric narcolepsy, boosting its market and offering new hope for young patients.

MoonLake Immunotherapeutics reports >80% ASAS40 response in Phase‑2 axSpA study, driving shares above $20 and boosting confidence in its Sonelokimab pipeline and 2025 financial outlook.

Tenaya Therapeutics is a biotech firm focused on curative therapies for heart disease, offering investors insight into its 2026 goals, market performance, and future potential.

Theralase Technologies’ laser therapy shows promise, but its financials are shaky—watch the 2026 EUU congress for a potential game‑changer.

Charlotte’s Web Holdings, a Boulder‑based cannabis‑infused wellness pioneer, showcases volatile stock, negative earnings, and high P/B—an intriguing watch for investors.

Discover ADC Therapeutics’ progress in antibody‑drug conjugate oncology—Swiss‑based, US‑focused, volatile stock, and its commitment to innovative cancer treatments.